BioWorld

Feb. 11, 2010

Alexza Brings in $40M from Biovail Deal to Develop Inhaled Antipsychotic

Alexza Pharmaceuticals Inc. and Biovail Laboratories International SRL have agreed to develop and commercialize Alexza's inhaled antipsychotic AZ-004 (Staccato loxapine) in the U.S. and Canada in a deal worth $130 million. (BioWorld Today) Read More

Mipomersen a Niche-Only Drug? Safety Drags Positive Phase III

Lysosomal Storage Disorder Gene Implicated in Stuttering

Daring 'TB' Different; Early Stage Aarden Working on PTP Drugs

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...